Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 388-399

  Sellares J ^a,b   De Freitas, D G ^a,b   Mengel, M ^a,b   Reeve, J ^a,b   Einecke, G ^c   Sis, B ^a,b   Hidalgo, L G ^a,b   Famulski, K ^a,b   Matas, A ^d   Halloran, P F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allograft failure; antibody mediated rejection; kidney transplantation; nonadherence

Indexed keywords

CALCINEURIN INHIBITOR; HLA ANTIBODY;

ACUTE KIDNEY FAILURE; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PHENOTYPE; POLYOMA VIRUS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT REFUSAL;

BIOPSY; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; KIDNEY; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84856411838     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03840.x     Document Type: Article

References (38)

1. Meier-Kriesche HU, Schold JD, Kaplan B,. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295. (Pubitemid 39013575)
2. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2010.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
4. Solez K, Axelsen RA, Benediktsson H, et al,. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422. (Pubitemid 23228698)
5. Nankivell BJ, Chapman JR,. Chronic allograft nephropathy: Current concepts and future directions. Transplant 2006; 81: 643-654.
6. Solez K, Colvin RB, Racusen LC, et al,. Banff '05 Meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526. (Pubitemid 46376465)
7. Halloran PF,. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002; 2: 195-200. (Pubitemid 36330234)
8. Haas M, Kraus ES, Samaniego-Picota M, Racusen LC, Ni W, Eustace JA,. Acute renal allograft rejection with intimal arteritis: Histologic predictors of response to therapy and graft survival. Kidney Int 2002; 61: 1516-1526. (Pubitemid 34304514)
9. Macdonald FI, Ashraf S, Picton M, et al,. Banff criteria as predictors of outcome following acute renal allograft rejection. Nephrol Dial Transplant 1999; 14: 1692-1697. (Pubitemid 29313047)
10. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ,. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-109. (Pubitemid 34753480)
11. El Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
12. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
13. Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
14. Halloran PF, de Freitas DG, Einecke G, et al,. An integrated view of molecular changes, histopathology, and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
15. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure 1. Transplantation 2010; 90: 68-74.
16. Hidalgo LG, Campbell PM, Sis B, et al,. De novo donor specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
17. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC,. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004; 77: 769-776. (Pubitemid 38366989)
18. Denhaerynck K, Dobbels F, Cleemput I, et al,. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: A literature review. Transpl Int 2005; 18: 1121-1133. (Pubitemid 41726755)
19. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR,. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009; 9: 2597-2606.
20. Prendergast MB, Gaston RS,. Optimizing medication adherence: An ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010; 5: 1305-1311.
21. Gaston RS, Hudson SL, Ward M, Jones P, Macon R,. Late renal allograft loss: Noncompliance masquerading as chronic rejection. Transplant Proc 1999; 31: 21S-23S. (Pubitemid 29282400)
22. Sis B, Mengel M, Haas M, et al,. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of banff working groups. Am J Transplant 2010; 10: 464-471.
23. Sellares J, de Freitas DG, Mengel M, et al,. Inflammation lesions in kidney transplant biopsies: Association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489-499.
24. Rasko JEJ, Bailey CG, Kowalczuk S, et al,. Genetics of human aminoacidurias. FEBS J 2008; 275: 98.
25. Famulski KS, Einecke G, Sis B, et al,. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant 2010; 10: 810-820.
26. Leggat JE Jr., Ojo AO, et al,. Long-term renal allograft survival. Prognostic implication of the timing of acute rejection episodes. Transplantation 1997; 63: 1268-1272. (Pubitemid 27212821)
27. Basadonna GP, Matas AJ, Gillingham KJ, et al,. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993; 55: 993-995. (Pubitemid 23150719)
28. McDonald S, Russ G, Campbell S, Chadban S,. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201-1208. (Pubitemid 46646787)
29. Woodward RS, Schnitzler MA, Lowell JA, Spitznagel EL, Brennan DC,. Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants. Am J Transplant 2001; 1: 69-73. (Pubitemid 33681684)
30. Cohen DJ, Murphy B,. Drug coverage for transplantation turns into political football: Big business trumps patients. Clin J Am Soc Nephrol 2010; 5: 746-747.
31. Zou Y, Stastny P, Susal C, Dohler B, Opelz G,. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300. (Pubitemid 47481451)
32. Terasaki PI, Ozawa M, Castro R,. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415. (Pubitemid 46096334)
33. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
34. Matas AJ, Gillingham KJ, Humar A, et al,. 2202 kidney transplant recipients with 10 years of graft function: What happens next? Am J Transplant 2008; 8: 2410-2419.
35. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ,. Immunologic factors: The major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842-1846. (Pubitemid 30027334)
36. Matas AJ,. Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 2011; 11: 687-692.
37. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
38. Halloran PF, de Freitas DG, Einecke G, et al,. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215-2222.